CN107921024B - 治疗或预防急性脑损伤或神经损伤的方法 - Google Patents

治疗或预防急性脑损伤或神经损伤的方法 Download PDF

Info

Publication number
CN107921024B
CN107921024B CN201680046586.2A CN201680046586A CN107921024B CN 107921024 B CN107921024 B CN 107921024B CN 201680046586 A CN201680046586 A CN 201680046586A CN 107921024 B CN107921024 B CN 107921024B
Authority
CN
China
Prior art keywords
posiphen
acute brain
acute
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680046586.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN107921024A (zh
Inventor
M·玛切奇尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anovis Biology
Original Assignee
QR Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by QR Pharma Inc filed Critical QR Pharma Inc
Publication of CN107921024A publication Critical patent/CN107921024A/zh
Application granted granted Critical
Publication of CN107921024B publication Critical patent/CN107921024B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201680046586.2A 2015-08-14 2016-08-12 治疗或预防急性脑损伤或神经损伤的方法 Active CN107921024B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562205431P 2015-08-14 2015-08-14
US62/205,431 2015-08-14
PCT/US2016/046794 WO2017030968A1 (en) 2015-08-14 2016-08-12 Methods of treatment or prevention of acute brain or nerve injuries

Publications (2)

Publication Number Publication Date
CN107921024A CN107921024A (zh) 2018-04-17
CN107921024B true CN107921024B (zh) 2021-09-10

Family

ID=56801810

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680046586.2A Active CN107921024B (zh) 2015-08-14 2016-08-12 治疗或预防急性脑损伤或神经损伤的方法

Country Status (9)

Country Link
US (2) US12042482B2 (enExample)
EP (1) EP3334425B1 (enExample)
JP (1) JP6862446B2 (enExample)
CN (1) CN107921024B (enExample)
AU (1) AU2016309815B2 (enExample)
CA (1) CA2994974C (enExample)
DK (1) DK3334425T3 (enExample)
TW (1) TW201717938A (enExample)
WO (1) WO2017030968A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201717938A (zh) 2015-08-14 2017-06-01 Ｑｒ製藥股份有限公司 治療或預防急性腦部或神經損傷的方法
EP3654957A4 (en) 2017-05-24 2021-06-23 Annovis Bio, Inc. PREVENTION OR TREATMENT OF DISEASE CONDITIONS DUE TO METAL DIS-HOMEOSTASIS BY ADMINISTERING POSIPHES TO HEALTHY OR SICK PEOPLE

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171750A (en) 1991-09-26 1992-12-15 The United States Of America As Represented By The Department Of Health And Human Services Substituted phenserines as specific inhibitors of acetylcholinesterase
US5409948A (en) 1992-11-23 1995-04-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating cognitive disorders with phenserine
WO1999002154A1 (en) 1997-07-09 1999-01-21 Axonyx Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
DE60124730T2 (de) 2000-03-03 2007-10-04 Eisai R&D Management Co., Ltd. Neue methoden unter verwendung von cholinesteraseinhibitoren
WO2002048150A2 (en) 2000-11-02 2002-06-20 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof
US6495700B1 (en) 2002-01-09 2002-12-17 Axonyx, Inc. Process for producing phenserine and its analog
US20040024043A1 (en) 2002-03-22 2004-02-05 Nigel Greig Method for treating cognitive disorders
WO2004034963A2 (en) 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
EP1617844A4 (en) 2003-04-03 2009-07-22 Prana Biotechnology Ltd TREATMENT OF NEUROLOGICAL DISEASES
US20050013869A1 (en) 2003-07-18 2005-01-20 Chaw Cheng Shu Sustained release formulation for carbamates and a method therefor
US20050182044A1 (en) 2004-02-17 2005-08-18 Bruinsma Gosse B. Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
WO2005091987A2 (en) 2004-03-19 2005-10-06 Axonyx, Inc. Method of treating down syndrome
WO2005089746A1 (en) 2004-03-19 2005-09-29 Axonyx, Inc. Dosage titration for treatment of cognitive disorders
EP1604686A1 (en) 2004-06-08 2005-12-14 Axonyx, Inc. Use of phenserine and a HMG CoA reductase inhibitor for delaying Alzheimer's disease progression
WO2008134618A2 (en) 2007-04-27 2008-11-06 The General Hospital Corporation Novel imaging tracers for early detection and treatment of amyloid plaques caused by alzheimer's disease and related disorders
WO2010117727A2 (en) 2009-03-30 2010-10-14 The General Hospital Corporation Phenserine and posiphen for treating neuropsychiatric and neurodegenerative conditions
US20120225922A1 (en) 2011-03-04 2012-09-06 Qr Pharma Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration
TW201717938A (zh) 2015-08-14 2017-06-01 Ｑｒ製藥股份有限公司 治療或預防急性腦部或神經損傷的方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"The Experimental Alzheimer"s Disease Drug Posiphen [(+)-Phenserine] Lowers Amyloid-beta Peptide Levels in Cell Culture and Mice";Lahiri, D. K. et. al.;《Journal of Pharmacology and Experimental Therapeutics》;20071231;第320卷(第1期);386–396页 *
"Traumatic brain injury and amyloid-β pathology: a link to Alzheimer"s disease?";Johnson, Victoria E. et.al.;《Nature Reviews Neuroscience》;20100531;第11卷;361-370页 *

Also Published As

Publication number Publication date
CA2994974A1 (en) 2017-02-23
TW201717938A (zh) 2017-06-01
JP6862446B2 (ja) 2021-04-21
EP3334425B1 (en) 2020-12-16
CA2994974C (en) 2024-04-09
JP2018523709A (ja) 2018-08-23
US20250000846A1 (en) 2025-01-02
DK3334425T3 (da) 2021-02-22
US20180228771A1 (en) 2018-08-16
CN107921024A (zh) 2018-04-17
EP3334425A1 (en) 2018-06-20
HK1253901A1 (en) 2019-07-05
US12042482B2 (en) 2024-07-23
WO2017030968A1 (en) 2017-02-23
AU2016309815B2 (en) 2022-04-07
AU2016309815A1 (en) 2018-02-15

Similar Documents

Publication Publication Date Title
US20250000846A1 (en) Methods of treatment or prevention of acute brain or nerve injuries
Puerta et al. Effect of the oral administration of nanoencapsulated quercetin on a mouse model of Alzheimer’s disease
AU2022265392B2 (en) Method and pharmaceutical composition for treating myopia
KR20250171484A (ko) 질환을 치료하기 위한 류신, 아세틸 류신, 및 관련된 유사체
AU2021396380A1 (en) Compositions for treating dry age-related macular degeneration (amd)
JP2023116748A (ja) 眼疾患の処置方法
WO2018217845A1 (en) Pharmaceutical combinations of zonisamide and praxipexole, and related methods, for treating synucleinopathies
HK1253901B (en) Methods of treatment or prevention of acute brain or nerve injuries
JP2014510115A (ja) 初期の緑内障における正常な視覚機能を回復するｐａｃａｐ（下垂体アデニル酸シクラーゼ活性化ポリペプチド）に基づく眼科用製剤
EP4496574A1 (en) Organic molecules for treating myelin pathologies
US11759451B2 (en) Therapeutic potential of glycopyrrolate and mexiletine for nervous system injury
Erb Prevalence of dry eye disease in glaucoma
Fernandes et al. Chronic ethanol forced administration from adolescence to adulthood reduces cell density in the rat spinal cord
JP2018523709A5 (enExample)
KR102153648B1 (ko) 산화적 스트레스로부터 성상세포를 보호하는 조성물
Sobstyl et al. Acute disseminated encephalitis in an adult patient addicted to heroin. Neuropathological, neuroradiological and clinical features
HK40002019A (zh) 用於治疗眼疾的方法
EP4648797A1 (en) Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of multiple sclerosis
Famà et al. Effects of calcium antagonists in the treatment of ophthalmic postherpetic neuralgia
Prodhan 2.7. Rho Kinase Inhibitor
Ali et al. Vitamin C Antioxidant Effects in Brain of Albino Mice after Seizures and Status Epilepticus Induced by Pentylene-tetrazole (PTZ)
Irache Effect of the oral administration of nanoencapsulated quercetin on a mouse model of Alzheimer's disease
Maki Impact of OAB Medications on CNS Function: The Science of Muscarinic Receptors.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: Pennsylvania, USA

Patentee after: Anovis biology

Address before: Pennsylvania, USA

Patentee before: QR PHARMA